Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes
Type 2 Diabetes Mellitus
About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring diabetes, exenatide, exendin-4, Amylin, Lilly
Eligibility Criteria
Inclusion Criteria: Diagnosis of type 2 diabetes, but otherwise healthy HbA1c between 6.6% and 9.5%, inclusive. Body mass index (BMI) of 25 kg/m2 to 40 kg/m2, inclusive. Treated with a stable dose of metformin for at least 2 months prior to screening. Exclusion Criteria: Patients previously in a study using exenatide. Treated with oral anti-diabetic medications other than metformin within 2 months of screening (thiazolidinediones within 5 months of screening). Treated with insulin within 3 months of screening.
Sites / Locations
- Research Site
- Research Site
- Research Site
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Exenatide Arm
Insulin Glargine Arm
Exenatide and Metformin
Insulin Glargine and Metformin